Ozono S, Hirao Y
Department of Urology, Nara Medical University.
Nihon Rinsho. 1998 Aug;56(8):2129-34.
There can be seen many investigations to examine the effects and benefits of total androgen blockade (TAB), combining an antiandrogen with surgical castration or a LH-RH analogue, for advanced prostate cancer. This review summarizes the concept, theory, method and clinical application of TAB. The concept of TAB was supported by reports that show a survival advantage using the combined blockade over LH-RH analogue alone. The theory of TAB proposes that suppression of all androgen production, adrenal and testicular androgen, should result in a better response than standard hormonal management such as castration and/or estrogens. In Japan, Chlormadinone acetate (100 mg twice daily) or Flutamide (375 mg three times daily) is orally administered and Leuprorelin acetate (3.75 mg every 4 weeks) or Goserelin acetate (3.6 mg every 4 weeks) is administered by hypodermic injection. There have been unresolved controversies surrounding this therapeutic modality, therefore future studies should help to define the role of TAB.
为研究全雄激素阻断(TAB)(将抗雄激素药物与手术去势或促性腺激素释放激素(LH-RH)类似物联合应用)对晚期前列腺癌的疗效和益处,已经开展了许多研究。本综述总结了TAB的概念、理论、方法及临床应用。有报告显示联合阻断比单独使用LH-RH类似物具有生存优势,这支持了TAB的概念。TAB理论提出,抑制所有雄激素生成,即肾上腺和睾丸雄激素,应比去势和/或雌激素等标准激素治疗产生更好的反应。在日本,口服醋酸氯地孕酮(每日2次,每次100mg)或氟他胺(每日3次,每次375mg),皮下注射醋酸亮丙瑞林(每4周3.75mg)或醋酸戈舍瑞林(每4周3.6mg)。围绕这种治疗方式一直存在未解决的争议,因此未来的研究应有助于明确TAB的作用。